RT Journal Article
T1 Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery
A1 Marques, Joana
A1 Valle-Delgado, Juan José
A1 Urbán, Patricia
A1 Baró, Elisabet
A1 Prohens, Rafel
A1 Mayor, Alfredo
A1 Cisteró, Pau
A1 Delves, Michael
A1 Sinden, Robert E
A1 Grandfils, Christian
A1 de Paz, José L
A1 García-Salcedo, José A
A1 Fernàndez-Busquets, Xavier
K1 Glycosaminoglycans
K1 Malaria
K1 Nanomedicine
K1 Plasmodium
K1 Targeted drug delivery
K1 Quitosano
K1 Recuento de eritrocitos
K1 Antimaláricos
K1 Insectos vectores
K1 Heparina
AB The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.
PB Elsevier
SN 1549-9634
YR 2017
FD 2017-02
LK http://hdl.handle.net/10668/2612
UL http://hdl.handle.net/10668/2612
LA en
NO Marques J, Valle-Delgado JJ, Urbán P, Baró E, Prohens R, Mayor A et al.Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery. Nanomedicine. 2017 Feb;13(2):515-525
NO Patent application: Heparin-lipidic nanoparticle conjugates. Inventors: Fernàndez-Busquets, X., Marques, J., Moles, E. Institutions: IBEC, ISGlobal. Application number: EP13152187.4; priority country: Europe; priority date: January 22, 2013.
DS RISalud
RD Apr 5, 2025